Thoracic Cancer Trial

Non-Small Cell Lung Cancer

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Official Title: Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 Non-Small Cell Lung Cancer

Physician and Research Staff Educational Material:

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

• • Physician Fact Sheet: schema, eligibility criteria, and treatment details.

Information and Assistance from the National Cancer Institute:

• • Locations and other information (coming soon)
  • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.

Trial EA5181 is federally registered on clinicaltrials.gov as record NCT04092283.

Return to Home Page | Review Other Active Trials